Potential of caveolae in the therapy of cardiovascular and neurological diseases

被引：16

作者：

Navarro, Gemma ^{[1
]}

Borroto-Escuela, Dasiel O. ^{[2
]}

Fuxe, Kjell ^{[2
]}

Franco, Rafael ^{[1
]}

机构：

[1] Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain

[2] Karolinska Inst, Dept Neurosci, Stockholm, Sweden

来源：

FRONTIERS IN PHYSIOLOGY | 2014年 / 5卷

基金：

英国医学研究理事会;

关键词：

arrhythmia; dementia; gene therapy; GPCR; ischemia reperfusion; neurodegeneration; Parkinson's disease; stem cell; ADENOSINE A(2A) RECEPTORS; PROTEIN-COUPLED-RECEPTORS; GLUTAMATE TYPE-1-ALPHA RECEPTOR; LATE SODIUM CURRENT; SARCOPLASMIC-RETICULUM; PLASMA-MEMBRANE; IN-VIVO; MEDIATED ENDOCYTOSIS; NEUROBLASTOMA-CELLS; ATRIAL-FIBRILLATION;

D O I：

10.3389/fphys.2014.00370

中图分类号：

Q4 [生理学];

学科分类号：

071003 ;

摘要：

Caveolae are membrane micro-domains enriched in cholesterol, sphingolipids and caveolins, which are transmembrane proteins with a hairpin-like structure. Caveolae participate in receptor-mediated trafficking of cell surface receptors and receptor-mediated signaling. Furthermore, caveolae participate in clathrin-independent endocytosis of membrane receptors. On the one hand, caveolins are involved in vascular and cardiac dysfunction. Also, neurological abnormalities in caveolin-1 knockout mice and a link between caveolin-1 gene haplotypes and neurodegenerative diseases have been reported. The aim of this article is to present the rationale for considering caveolae as potential targets in cardiovascular and neurological diseases.

引用

页数：8

共 50 条

[21] Stem cell therapy for neurological diseases
Hermann, A.
Storch, A.
[J]. AKTUELLE NEUROLOGIE, 2007, 34 (02) : 85 - 93
[22] Caveolae and caveolin-1: novel potential targets for the treatment of cardiovascular
Frank, Philippe G.
Hassan, Ghada S.
Rodriguez-Feo, Juan A.
Lisanti, Michael P.
[J]. CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (17) : 1761 - 1769
[23] Sorting receptor sortilin—a culprit in cardiovascular and neurological diseases
Anne-Sophie Carlo
Anders Nykjaer
Thomas E. Willnow
[J]. Journal of Molecular Medicine, 2014, 92 : 905 - 911
[24] Association of bullous Pemphigoids with neurological, endocrinological and Cardiovascular Diseases
Huebner, F.
Koenig, I. R.
Zillikens, D.
Linder, R.
Schmidt, E.
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 100 - 100
[25] Testosterone therapy and cardiovascular diseases
Cittadini, Antonio
Isidori, Andrea M.
Salzano, Andrea
[J]. CARDIOVASCULAR RESEARCH, 2022, 118 (09) : 2039 - 2057
[26] Gene therapy for cardiovascular diseases
Elizabeth G. Nabel
[J]. Journal of Nuclear Cardiology, 1999, 6 : 69 - 75
[27] Gene therapy for cardiovascular diseases
Brugada, R
Roberts, R
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (09) : 1385 - 1393
[28] HDL therapy for cardiovascular diseases
Franceschini, G.
[J]. ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 301 - 301
[29] Photodynamic Therapy and Cardiovascular Diseases
Oskroba, Aleksander
Bartusik-Aebisher, Dorota
Mysliwiec, Angelika
Dynarowicz, Klaudia
Cieslar, Grzegorz
Kawczyk-Krupka, Aleksandra
Aebisher, David
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (05)
[30] Antithrombotic therapy in cardiovascular diseases
Marx, Nikolaus
[J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2020, 145 (14) : 947 - 947

← 1 2 3 4 5 →